TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39084177
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of age, HbA1c, diastolic blood pressure, triglycerides and smoking at T1D onset
Study: 39084177
Drug: HbA1c, triglycerides
Approvals — FDA: no, EMA: no, PMDA: no
Description: HbA1c, triglycerides and insulin dose 3-months post-diagnosis
Study: 39084489
Drug: KT-474, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: KT-474, a targeted degrader of IRAK4, ex vivo treatment of PBMCs from healthy volunteers and patients with HS.
Study: 39084489
Drug: KT-474, ex
Approvals — FDA: no, EMA: no, PMDA: no
Description: KT-474, ex vivo treatment of toll-like receptor-stimulated healthy donor monocytes.
Study: 39084827
Drug: Jewel patch-wearable
Normalized name: jewel weed whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jewel patch-wearable cardioverter-defibrillator (P-WCD)
Study: 39084863
Drug: Healthy mutation
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy mutation carriers (HMC) with elevated t-tau (>290 pg/mL)
Study: 39084935
Drug: Random forest
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random forest algorithm for predicting PD-L1 expression and immunotherapy prognosis
Study: 39084935
Drug: Random forest
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random forest model predicting treatment response in PD-L1 high-expression patients
Study: 39085322
Drug: Topical solution
Normalized name: Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical solution of plant terpenes containing camphor, menthol, eugenol, eucalyptol, and vanillin with 15% DMSO, 1% limonene, and rosemary oil applied topically twice daily.
Study: 39085664
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Auriculotherapy and Acupuncture (AUR-ACU)
Study: 39085831
Drug: SMP (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMP (6 weekly sessions)
Study: 39085831
Drug: SMP +
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMP + HBCC (6 weekly sessions)
Study: 39085927
Drug: Multidisciplinary lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary lifestyle interventions (MLI) - 3 months of weekly 2-hour sessions on diet education, yoga, music therapy, and cognitive skills training.
Study: 39086857
Drug: Functional fitness
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional fitness training and mastering physical literacy class twice a week with buddy peer support for 12 weeks, including reflective writing journal.
Study: 39087355
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no valsartan treatment)
Study: 39087734
Drug: Concurrent trauma-focused
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent trauma-focused and personality disorder treatment
Study: 39087734
Drug: Only trauma-focused
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only trauma-focused treatment
Study: 39087868
Drug: Amoxicillin 1000
Normalized name: amoxicillin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 1000 mg three times daily before meals (BM-TID)
Study: 39087868
Drug: Amoxicillin 1000
Normalized name: amoxicillin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 1000 mg three times daily after meals (AM-TID)
Study: 39087868
Drug: Amoxicillin 750
Normalized name: amoxicillin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 750 mg four times daily after meals (AM-QID)
Study: 39088062
Drug: Pre-hospital heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-hospital heparin administration
Study: 39088062
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no pre-hospital heparin)
Study: 39088076
Drug: Prolonged awake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged awake prone positioning (target > 12 h daily for 7 days)
Study: 39088212
Drug: ω-3 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω-3 PUFA (1.65 g, 975 mg EPA and 650 mg DHA)
Study: 39088212
Drug: ω-3 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω-3 PUFA (1.65 g, 975 mg EPA and 650 mg DHA) among APOE*E4 carriers
Study: 39088370
Drug: Binaural beats
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binaural beats intervention, details on dosage and duration not available
Study: 39088398
Drug: Apalutamide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apalutamide plus androgen deprivation therapy (ADT); 240 mg daily for 12 cycles (28-day cycles)
Study: 39088398
Drug: Apalutamide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apalutamide plus ADT; 12 months after treatment completion
Study: 39088510
Drug: Higher number
Normalized name: Derma Numb
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher number of daily steps
Study: 39088766
Drug: Nurse-led two-session
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-led two-session intervention (focused on breathing techniques, postural positions, and fan therapy)
Study: 39088774
Drug: Standard-dose FFX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose FFX
Study: 39089004
Drug: Befotertinib 50
Normalized name: Befotertinib
DrugBank: Befotertinib (DB18844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Befotertinib 50 mg once daily (cohort A)
Study: 39089004
Drug: Befotertinib 75-100
Normalized name: Befotertinib
DrugBank: Befotertinib (DB18844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Befotertinib 75-100 mg once daily (cohort B)
Study: 39089004
Drug: Befotertinib 50
Normalized name: Befotertinib
DrugBank: Befotertinib (DB18844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Befotertinib 50 mg once daily (cohort A) with brain metastasis
Study: 39089004
Drug: Befotertinib 50
Normalized name: Befotertinib
DrugBank: Befotertinib (DB18844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Befotertinib 50 mg once daily (cohort A) without brain metastasis
Study: 39089004
Drug: Befotertinib 75-100
Normalized name: Befotertinib
DrugBank: Befotertinib (DB18844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Befotertinib 75-100 mg once daily (cohort B) with brain metastasis
Study: 39089004
Drug: Befotertinib 75-100
Normalized name: Befotertinib
DrugBank: Befotertinib (DB18844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Befotertinib 75-100 mg once daily (cohort B) without brain metastasis
Study: 39089305
Drug: Tepotinib plus
Normalized name: Tepotinib
DrugBank: Tepotinib (DB15133)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tepotinib plus osimertinib (oral tepotinib 500 mg plus oral osimertinib 80 mg once daily)
Study: 39089652
Drug: Probiotic preparation
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic preparation containing Lactobacillus helveticus Rosell®-52 and Bifidobacterium longum Rosell®-175 over 60 days
Study: 39089718
Drug: Access to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Access to protein signature with top-down treatment algorithm (anti-tumour necrosis factor agent with/without an immunomodulator)
Study: 39089718
Drug: Clinical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical management based on stepwise escalation of treatment after failure of first-line treatment
Study: 39090192
Drug: ADE-RS5 (5-gene-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADE-RS5 (5-gene-drug resistance score)
Study: 39090323
Drug: N-L-NMMA at
Normalized name: N-ACETYL L-TYROSINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-L-NMMA at 250 μg/kg per minute combined with trimethaphan at 4 mg/min
Study: 39090589
Drug: Reported malaria
Normalized name: Plasmodium malariae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reported malaria treatment
Study: 39090589
Drug: Reported malaria
Normalized name: Plasmodium malariae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reported malaria treatment among febrile individuals
Study: 39091670
Drug: Deoxycytidine/deoxythymidine (dC/dT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deoxycytidine/deoxythymidine (dC/dT) combination therapy
Study: 39091669
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment (Allisartan starting at 80 mg/day, increased to 160 mg/day at month 2, combined with amlodipine 2.5 mg/day at month 4 if BP remained uncontrolled)
Study: 39091673
Drug: 2-dose mRNA-1273
Normalized name: MRNA-1273 SARS-COV-2
DrugBank: Moderna COVID-19 Vaccine (DB15654)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose mRNA-1273 100 μg
Study: 39091673
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of mRNA-1273 50 μg
Study: 39093262
Drug: Inclisiran 300
Normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inclisiran 300 mg sodium (284 mg inclisiran)
Study: 39093380
Drug: NSPIT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSPIT plus 500 mg of oral systemic metronidazole three times a day for 7 days
Study: 39093661
Drug: Tildrakizumab 100
Normalized name: tildrakizumab 100 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tildrakizumab 100 mg at weeks 0 and 4, then every 12 weeks through week 52
Study: 39093662
Drug: Nutrafol Women's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrafol Women's Vegan Capsules, Nutraceutical Wellness, Inc.
Study: 39094432
Drug: CER-0001 (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: CER-0001 (up to 30 g twice a day)
Study: 39094560
Drug: NACRT and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NACRT and PD-1 antibody sintilimab
Study: 39094743
Drug: PegIFN-α-2a treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIFN-α-2a treatment for 48 weeks
Study: 39095571
Drug: Behavioral Health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Health (BH) care management including cognitive behavioral therapy, medication adjustments, and case management
Study: 39095597
Drug: L. major-infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. major-infected Phlebotomus duboscqi
Study: 39095759
Drug: Digital subtraction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital subtraction angiography-guided pancreatic arterial infusion (PAI) of GEMOX chemotherapy
Study: 39095759
Drug: Intravenous chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous chemotherapy (IVC) of GEMOX
Study: 39095866
Drug: Caplacizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caplacizumab (10 mg daily) with therapeutic plasma exchange (TPE) and immunosuppression for 30 days post-TPE
Study: 39095866
Drug: Rituximab administered
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab administered to patients with inhibitor boosting (88.9%) after TPE completion
Study: 39095866
Drug: Rituximab administered
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab administered to patients without inhibitor boosting prior to TPE completion
Study: 39095919
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1500 mg)
Study: 39096659
Drug: ISIS721744 (antisense
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS721744 (antisense therapy to block prekallikrein), one subcutaneous dose
Study: 39096924
Drug: Molecularly guided
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecularly guided therapy (MGT)
Study: 39096929
Drug: iscalimab 150
Normalized name: Iscalimab
DrugBank: Iscalimab (DB15260)
Approvals — FDA: no, EMA: no, PMDA: no
Description: iscalimab 150 mg
Study: 39096929
Drug: iscalimab 300
Normalized name: Iscalimab
DrugBank: Iscalimab (DB15260)
Approvals — FDA: no, EMA: no, PMDA: no
Description: iscalimab 300 mg
Study: 39096929
Drug: iscalimab 600
Normalized name: Iscalimab
DrugBank: Iscalimab (DB15260)
Approvals — FDA: no, EMA: no, PMDA: no
Description: iscalimab 600 mg
Study: 39097000
Drug: Happy Mother-Healthy
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Happy Mother-Healthy Baby (HMHB) program based on cognitive behavioral therapy
Study: 39097315
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (annual oral health awareness visit)
Study: 39097500
Drug: Nivolumab ±
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab ± ipilimumab second-line immunotherapy
Study: 39097566
Drug: Personalized insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Personalized insulin dosing using reinforcement learning for high-fat meals
Study: 39097566
Drug: Personalized insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Personalized insulin dosing using reinforcement learning for meals followed by aerobic exercises
Study: 39097916
Drug: chemotherapy (nCT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy (nCT)
Study: 39097924
Drug: Tetracycline 500 mg
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline 500 mg three times daily (TET-T)
Study: 39097924
Drug: Tetracycline 500 mg
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline 500 mg four times daily (TET-F)
Study: 39098048
Drug: Dehydrated human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dehydrated human amniotic/chorionic membrane (dHACM) treatment following excisional debridement
Study: 39098321
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg fosravuconazole
Study: 39098321
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg fosravuconazole
Study: 39098321
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of fosravuconazole
Study: 39098325
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus ≤6 monthly incentives (22,500 Tanzanian Shillings, about US$10 each), conditional on visit attendance.
Study: 39098432
Drug: Preoperative single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative single-dose partial breast irradiation (PBI) followed by breast-conserving surgery (BCS)
Study: 39098454
Drug: High pre-treatment
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High pre-treatment levels of IL-6 (quartile 4 versus 1)
Study: 39098454
Drug: Pre-treatment inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment inflammatory markers
Study: 39098658
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment in HR patients
Study: 39098658
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment in VHR patients
Study: 39099085
Drug: FLU-aQIV and
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLU-aQIV and RSVPreF3 OA co-administration (Co-Ad)
Study: 39099085
Drug: Sequential administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential administration of FLU-aQIV and RSVPreF3 OA (Control)
Study: 39100571
Drug: Vortioxetine (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine (10-20 mg/day) for 8 weeks
Study: 39101472
Drug: Inclisiran as
Normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inclisiran as adjunct to high-intensity statin therapy with or without ezetimibe
Study: 39101472
Drug: Ezetimibe as
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ezetimibe as adjunct to high-intensity statin therapy
Study: 39101472
Drug: Evolocumab as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab as adjunct to high-intensity statin therapy and ezetimibe
Study: 39101472
Drug: Placebo as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as adjunct to high-intensity statin therapy with or without ezetimibe
Study: 39101607
Drug: SPT (Surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPT (Surgery with Postoperative Physical Therapy)
Study: 39101607
Drug: PTA (Physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTA (Physical Therapy Alone)
Study: 39101654
Drug: Neoadjuvant immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant immunotherapy (NAIT)
Study: 39101738
Drug: Knee arthroscopy
Normalized name: Bos taurus knee joint preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knee arthroscopy in addition to exercise therapy (n=150)
Study: 39101738
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy alone (n=150)
Study: 39102049
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl cysteine (NAC) 2400 mg/day
Study: 39102111
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein and low glycemic load diet (1.3-1.4 g/kg/day)
Study: 39102249
Drug: Multidisciplinary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary treatment (physiotherapy plus cognitive behavioral therapy)
Study: 39102622
Drug: MDT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDT plus systemic therapy
Study: 39102622
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy (control)
Study: 39102624
Drug: Ipilimumab 10
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 10 mg/kg every 3 weeks for four doses and then every 12 weeks for 1 year
Study: 39102712
Drug: Mind-body medicine
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mind-body medicine stress management and lifestyle modification (MBM) program, duration 9 months, guided intervention group (IG)
Study: 39102712
Drug: Mind-body medicine
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mind-body medicine program (both guided and self-directed)
Study: 39102756
Drug: Camrelizumab, apatinib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab, apatinib, and capecitabine combination therapy
Study: 39102832
Drug: Atezolizumab 1200
Normalized name: atezolizumab 1200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 1200 mg plus chemotherapy (carboplatin and paclitaxel)
Study: 39103234
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of monofocal and EDOF IOL implantation
Study: 39103546
Drug: CC (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC (control cracker with conventional flour)
Study: 39103661
Drug: Nebulised modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised modified cyanoacrylate (1 mL) for anastomotic reinforcement
Study: 39103923
Drug: Individualized exercise-intensity
Normalized name: California intense cedar pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized exercise-intensity prescription targeting pleasure
Study: 39103947
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rTMS and EEG-guided neurofeedback
Study: 39105058
Drug: apitegromab 20
Normalized name: Apitegromab
DrugBank: Apitegromab (DB16096)
Approvals — FDA: no, EMA: no, PMDA: no
Description: apitegromab 20 mg/kg by intravenous infusion every 4 weeks
Study: 39105067
Drug: Ravulizumab (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ravulizumab (intravenous every 4-8 weeks, dosage depending on body weight)
Study: 39105794
Drug: tislelizumab plus
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tislelizumab plus low-dose bevacizumab (Bev)
Study: 39105849
Drug: Eribulin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin and nivolumab combination
Study: 39106067
Drug: Everolimus (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (10 mg orally daily for 54 weeks)
Study: 39106081
Drug: oleclumab 3,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: oleclumab 3,000 mg (cohort B)
Study: 39107131
Drug: nivolumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: nivolumab monotherapy
Study: 39107157
Drug: Cabozantinib (2L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib (2L therapy)
Study: 39107157
Drug: Other therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other therapies (2L therapy)
Study: 39107270
Drug: CoronaVac® (3-μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoronaVac® (3-μg injections, two doses, 28 days apart)
Study: 39107706
Drug: TabCAT-BHA intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: TabCAT-BHA intervention (tablet-based brain health assessment) with practice supports including education, digital tools, and registered nurse support.
Study: 39107737
Drug: Roxolid implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxolid implants
Study: 39107820
Drug: Screening and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening and Treatment of Anxiety and Depression (STAND)
Study: 39107820
Drug: Original online
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original online therapy intervention
Study: 39108325
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) at 600 mg twice daily
Study: 39108617
Drug: sacituzumab govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: sacituzumab govitecan (10 mg/kg)
Study: 39109221
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg ivermectin